Company intelligence / Profile preview
Helixmith
Seoul, South Koreahelixmith.com ↗
- Ownership
- Private
- Employees
- ~72
- Development stage
- Phase 3
01
Overview
Helixmith’s lead asset Engensis (VM202) has advanced to Phase 3 clinical trials in diabetic peripheral neuropathy and diabetic foot ulcer. Other indications are at earlier stages. The company also has a broad pipeline of preclinical to early clinical stage assets targeting neuromuscular diseases and solid tumors with both gene therapies and antibody-based approaches
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularMen's HealthNephrologyEndocrinologyNeurology
- Modalities
- Gene therapy (plasmid DNA)antibody therapeuticsAAV vector gene therapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Biosolution Co., Ltd. — management rights transfer agreement signed September 2024Ewha Womans University Medical Center — joint research on cell/gene therapy since November 2022Cartexell & GI Cell — three-party MOU on cell/gene therapy products since April 2022
Beyond the preview
Go deeper on Helixmith.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helixmith.